Zymeworks Inc.: EVP, Head of R&D Adam Schayowitz sold 13,832 shares

What happened

• Adam Schayowitz, EVP, Head of R&D, acquired 37,037 shares through exercise/conversion of a derivative (reported as code M) at $0.00, and reported a derivative disposition of 37,037 shares at $0.00. He also sold 13,832 shares in an open market or private sale at a weighted average price of $25.85 for $357,557.

Key details

• Transaction date: Oct 9, 2026.
• Prices reported: derivative acquisition 37,037 shares @ $0.00; sale 13,832 shares @ $25.85 (weighted average); derivative disposition 37,037 shares @ $0.00.
• Price range for the sale: $25.85 to $25.88 (per filing footnote).
• Shares owned after the transactions: not reported in this filing.
• Relevant footnotes from the filing:
  • The 37,037 shares represent one third of RSUs granted Oct 9, 2025 that vested (each RSU equals one share).
  • The 13,832 shares were sold to cover tax withholding and fees under a mandatory "sell to cover" provision and were not a discretionary sale by the reporting person.
  • The sale price is a weighted average; the filing will provide per-lot prices on request.
• Filing timeliness: the Form 4 was filed on Oct 9, 2026 (same day as the report date).

Why it may matter

• The filing shows RSUs vested and were converted to common stock (derivative exercise/conversion), and a portion of shares from that vesting were sold to satisfy tax withholding (sell-to-cover).
• The filing does not show why the insider traded or why the company acted.